Clinical Trials for Other Solid Tumor

A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial focuses on patients with advanced solid tumors carrying KRAS or EGFR mutations who have relapsed or are refractory to standard treatments, using the oral SHP2 inhibitor HBI-2376 to target pathways involved in cancer cell survival and proliferation.

ClinicalTrials.gov ID: NCT05163028

A First-In-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 764532 Administered by Parenteral Route in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial involves adults with DLL3-positive small cell lung carcinoma and neuroendocrine carcinomas, including those with brain metastases under specific conditions, who have exhausted standard therapies. The investigational treatment, BI 764532, is a bispecific antibody designed to engage T-cells by linking DLL3 on cancer cells with CD3 on T-cells, aiming to determine its maximum tolerated dose and evaluate its safety and anti-tumor activity.

ClinicalTrials.gov ID: NCT04429087

A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets patients with advanced, untreated, unresectable, or metastatic non-small cell lung cancer with the KRAS G12C mutation, including both squamous and non-squamous histology, and involves treatment with a combination of adagrasib, a KRAS G12C inhibitor, pembrolizumab, and standard chemotherapy agents.

ClinicalTrials.gov ID: NCT05609578

A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON).

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial investigates the efficacy of durvalumab and tremelimumab combined with platinum-based chemotherapy compared to pembrolizumab with similar chemotherapy for first-line treatment in stage IV metastatic non-squamous NSCLC patients with STK11, KEAP1, or KRAS mutations. Durvalumab and tremelimumab are monoclonal antibodies that target the PD-L1 and CTLA-4 pathways, respectively.

ClinicalTrials.gov ID: NCT06008093

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates DF1001, a tri-specific NK cell engager targeting HER2-expressing tumors, in patients with locally advanced or metastatic solid tumors including HER2-activated non-small cell lung cancer and breast, gastric, esophageal, and urothelial bladder cancers, as monotherapy or combined with treatments like nivolumab, Nab-paclitaxel, and Sacituzumab govitecan-hziy.

ClinicalTrials.gov ID: NCT04143711

A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates CHS-388, a monoclonal antibody targeting IL-27 to reduce immunosuppression, as both monotherapy and in combination with pembrolizumab and toripalimab, in adult patients with advanced ccRCC, HCC, or NSCLC who have progressed after standard treatments. It focuses on those with limited treatment options, assessing safety and preliminary efficacy across different treatment arms based on previous therapies and tumor types.

ClinicalTrials.gov ID: NCT04374877

Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates MCLA-129, a bispecific antibody targeting EGFR and c-MET, administered alone or with osimertinib or chemotherapy, in patients with advanced NSCLC, GC/GEJ, HNSCC, and ESCC who progressed after standard treatments or possess relevant genetic mutations. Participants require measurable disease, ECOG status 0 or 1, and a life expectancy of at least 12 weeks.

ClinicalTrials.gov ID: NCT04868877

Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adults with advanced solid tumors resistant to PD-(L)1 inhibitors, using RAPA-201, an investigational immunotherapy leveraging autologous T cells engineered for temsirolimus resistance and favorable immune traits, combined with the chemotherapy regimen of carboplatin and paclitaxel.

ClinicalTrials.gov ID: NCT05144698

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial evaluates the combination of quaratusugene ozeplasmid, a systemic gene therapy encapsulating the TUSC2 tumor suppressor gene, with osimertinib in patients aged 18 and over with EGFR-mutant, metastatic Non-Small Cell Lung Cancer (NSCLC) who have progressed after at least four months on osimertinib. This combination targets cells with EGFR mutations, offering a potential treatment option compared to standard platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT04486833

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates TSR-022, a TIM-3 checkpoint inhibitor, as monotherapy or in combination with therapies such as anti-PD-1 drugs in adult patients with advanced or metastatic solid tumors, including NSCLC and HCC, who have previously been treated with standard therapies. Eligible patients should have measurable disease and agree to biopsies for TIM-3 expression assessment.

ClinicalTrials.gov ID: NCT02817633